The discoverer of N6 doesn't seem to agree:
> As potent as N6 is, HIV can still develop a resistance to it, making it a poor candidate as a "monotherapy" or stand-alone treatment, said Connors.
If Connors is right, finding the N6 sequence alone, and in fact even delivering a functional N6 with a perfectly safe and effective vector, probably isn't adequate. Given the genomic integration of HIV, that's no surprise.
And I don't think it is entirely clear if expressing that antibody alone is enough to defeat HIV, especially as it targets the immune system itself. If antibodies are the solution, then developing a vaccine that triggers the production of suitable antibodies is probably the better way forward.
The vaccines that trigger antibody production actually are being made.
>RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVVSA [1] [2]
Yet the current, engineering-style challenge is getting that protein sequence expressed in the right place, at the right time, without disturbing its environment, etc.
It's hard to compare the difficulty or danger of trying a therapy with 'scientific' risks versus 'engineering' risks. At first glance it might appear that now that the scientific problem has been solved (to a particular extent), that the engineering challenge is easy. However, the details really do matter. And not having all the facts, can in fact be lethal. On the other hand, to some extent, the scientific challenge really is the limiting capability, whereas the engineering challenge could be considered one of degree and risk. One this guy, for better or worse, was willing to take.
[1] https://www.ncbi.nlm.nih.gov/protein/1079417984
[2] http://www.cell.com/immunity/fulltext/S1074-7613(16)30438-1